0001209191-23-060008.txt : 20231229
0001209191-23-060008.hdr.sgml : 20231229
20231229163439
ACCESSION NUMBER: 0001209191-23-060008
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231228
FILED AS OF DATE: 20231229
DATE AS OF CHANGE: 20231229
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lowrance David L
CENTRAL INDEX KEY: 0001408498
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-32157
FILM NUMBER: 231528149
MAIL ADDRESS:
STREET 1: 422 WILLIAM WALLACE DRIVE
CITY: FRANKLIN
STATE: TN
ZIP: 37064
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Savara Inc
CENTRAL INDEX KEY: 0001160308
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 841318182
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6836 BEE CAVE ROAD
STREET 2: BUILDING 3, SUITE 201
CITY: AUSTIN
STATE: TX
ZIP: 78746
BUSINESS PHONE: 51285113796
MAIL ADDRESS:
STREET 1: 6836 BEE CAVE ROAD
STREET 2: BUILDING 3, SUITE 201
CITY: AUSTIN
STATE: TX
ZIP: 78746
FORMER COMPANY:
FORMER CONFORMED NAME: Mast Therapeutics, Inc.
DATE OF NAME CHANGE: 20130312
FORMER COMPANY:
FORMER CONFORMED NAME: ADVENTRX PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20030613
FORMER COMPANY:
FORMER CONFORMED NAME: BIOKEYS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20010928
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-12-28
0
0001160308
Savara Inc
SVRA
0001408498
Lowrance David L
ONE SUMMIT SQUARE,
1717 LANGHORNE NEWTOWN ROAD, SUITE 300
LANGHORNE
PA
19047
0
1
0
0
CHIEF FINANCIAL OFFICER
0
Common Stock
2023-12-28
4
S
0
10000
4.7131
D
342355
D
Represents shares sold to satisfy tax liability upon the vesting of restricted stock units.
The price is a weighted average sales price. The sale prices ranged from $4.70 to $4.795. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
/s/ David Lowrance
2023-12-29